These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 29209571)

  • 1. Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab.
    Yuan Y; Kos FJ; He TF; Yin HH; Li M; Hardwick N; Zurcher K; Schmolze D; Lee P; Pillai RK; Chung V; Diamond DJ
    Oncoimmunology; 2017; 6(12):e1363138. PubMed ID: 29209571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of safety and efficacy of p53MVA vaccine combined with pembrolizumab in patients with advanced solid cancers.
    Chung V; Kos FJ; Hardwick N; Yuan Y; Chao J; Li D; Waisman J; Li M; Zurcher K; Frankel P; Diamond DJ
    Clin Transl Oncol; 2019 Mar; 21(3):363-372. PubMed ID: 30094792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunologic Signatures of Peripheral Blood T Cells Reveal the Outcome of p53MVA Vaccine and Pembrolizumab Treatment in Patients with Advanced Ovarian Cancer.
    Kos FJ; Frankel P; Cristea M; Eng M; Tinsley R; Dempsey S; Ruel N; Stewart D; Dellinger TH; Diamond DJ
    Cancer Res Commun; 2023 Dec; 3(12):2585-2595. PubMed ID: 38032111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53-specific CD8+ T-cell responses.
    Hardwick NR; Carroll M; Kaltcheva T; Qian D; Lim D; Leong L; Chu P; Kim J; Chao J; Fakih M; Yen Y; Espenschied J; Ellenhorn JD; Diamond DJ; Chung V
    Clin Cancer Res; 2014 Sep; 20(17):4459-70. PubMed ID: 24987057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overcoming immunosuppression to enhance a p53MVA vaccine.
    Hardwick N; Chung V; Cristea M; Ellenhorn JD; Diamond DJ
    Oncoimmunology; 2014 Nov; 3(10):e958949. PubMed ID: 25941580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.
    Winer EP; Lipatov O; Im SA; Goncalves A; Muñoz-Couselo E; Lee KS; Schmid P; Tamura K; Testa L; Witzel I; Ohtani S; Turner N; Zambelli S; Harbeck N; Andre F; Dent R; Zhou X; Karantza V; Mejia J; Cortes J;
    Lancet Oncol; 2021 Apr; 22(4):499-511. PubMed ID: 33676601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Case Report: Significant Response to the Combination of Lenvatinib and Immune Checkpoint Inhibitor in a Patient With Heavily Pretreated Metastatic Triple Negative Breast Cancer.
    Lee JS; Yost SE; Yuan Y
    Front Oncol; 2020; 10():582185. PubMed ID: 33505906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
    Cortes J; Cescon DW; Rugo HS; Nowecki Z; Im SA; Yusof MM; Gallardo C; Lipatov O; Barrios CH; Holgado E; Iwata H; Masuda N; Otero MT; Gokmen E; Loi S; Guo Z; Zhao J; Aktan G; Karantza V; Schmid P;
    Lancet; 2020 Dec; 396(10265):1817-1828. PubMed ID: 33278935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.
    Loi S; Giobbie-Hurder A; Gombos A; Bachelot T; Hui R; Curigliano G; Campone M; Biganzoli L; Bonnefoi H; Jerusalem G; Bartsch R; Rabaglio-Poretti M; Kammler R; Maibach R; Smyth MJ; Di Leo A; Colleoni M; Viale G; Regan MM; André F;
    Lancet Oncol; 2019 Mar; 20(3):371-382. PubMed ID: 30765258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature.
    Feng D; Guan Y; Liu M; He S; Zhao W; Yin B; Liang J; Li Y; Wang J
    Front Immunol; 2021; 12():608292. PubMed ID: 34135884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study.
    Schmid P; Salgado R; Park YH; Muñoz-Couselo E; Kim SB; Sohn J; Im SA; Foukakis T; Kuemmel S; Dent R; Yin L; Wang A; Tryfonidis K; Karantza V; Cortés J; Loi S
    Ann Oncol; 2020 May; 31(5):569-581. PubMed ID: 32278621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study.
    Cortellini A; Cannita K; Tiseo M; Cortinovis DL; Aerts JGJV; Baldessari C; Giusti R; Ferrara MG; D'Argento E; Grossi F; Guida A; Berardi R; Morabito A; Genova C; Antonuzzo L; Mazzoni F; De Toma A; Signorelli D; Gelibter A; Targato G; Rastelli F; Chiari R; Rocco D; Gori S; De Tursi M; Mansueto G; Zoratto F; Filetti M; Bracarda S; Citarella F; Russano M; Cantini L; Nigro O; Buti S; Minuti G; Landi L; Ricciardi S; Migliorino MR; Natalizio S; Simona C; De Filippis M; Metro G; Adamo V; Russo A; Spinelli GP; Di Maio M; Banna GL; Friedlaender A; Addeo A; Pinato DJ; Ficorella C; Porzio G
    Eur J Cancer; 2021 May; 148():24-35. PubMed ID: 33721704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of Pembrolizumab with Electrochemotherapy in Cutaneous Metastases from Melanoma: A Comparative Retrospective Study from the InspECT and Slovenian Cancer Registry.
    Campana LG; Peric B; Mascherini M; Spina R; Kunte C; Kis E; Rozsa P; Quaglino P; Jones RP; Clover AJP; Curatolo P; Giorgione R; Cemazar M; Terlizzi F; Bosnjak M; Sersa G
    Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and H.
    Gubens MA; Sequist LV; Stevenson JP; Powell SF; Villaruz LC; Gadgeel SM; Langer CJ; Patnaik A; Borghaei H; Jalal SI; Fiore J; Saraf S; Raftopoulos H; Gandhi L
    Lung Cancer; 2019 Apr; 130():59-66. PubMed ID: 30885353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pembrolizumab in the preoperative setting of triple-negative breast cancer: safety and efficacy.
    Barroso-Sousa R; Tolaney SM
    Expert Rev Anticancer Ther; 2020 Nov; 20(11):923-930. PubMed ID: 32930616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strong and Sustained Response to Treatment with Carboplatin plus Nab-Paclitaxel in a Patient with Metastatic, Triple-Negative, BRCA1-Positive Breast Cancer.
    Shakir AR
    Case Rep Oncol; 2014 Jan; 7(1):252-9. PubMed ID: 24847251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
    Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
    Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Folliculotropic Cutaneous Metastases and Lymphangitis Carcinomatosa: When Cutaneous Metastases of Breast Carcinoma Are Mistaken for Cutaneous Infections.
    Paolino G; Panetta C; Didona D; Donati M; Donati P
    Acta Dermatovenerol Croat; 2016 Jun; 24(2):154-7. PubMed ID: 27477179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
    Iversen TZ
    Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy.
    Finazzi T; Rordorf T; Ikenberg K; Huber GF; Guckenberger M; Garcia Schueler HI
    BMC Cancer; 2018 Apr; 18(1):395. PubMed ID: 29625593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.